Home
/
Treatment
/
2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt

2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt

	2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt
Trade Name
Orphan Indication	Multiple myeloma
USA Market Approval	USA
USA Designation Date	2008-12-22 00:00:00
Sponsor	EntreMed, Inc.;Research Triangle Park Center, Suite 400;Durham, North Carolina, 27703

Related Access Program

AbbVie – Multiple Myeloma Janssen Research & Development, LLC – Multiple Myeloma Dana-Farber Cancer Institute – Multiple Myeloma Bristol-Myers Squibb – Multiple Myeloma Peking University – Multiple Myeloma Novartis Pharmaceuticals – Multiple Myeloma Onyx Pharmaceuticals, Inc., an Amgen subsidiary – Multiple myeloma